Rigel Pharmaceuticals RIGL Accrued research and development

Accrued research and development at other companies

Arcus BiosciencesRCUS

$98M+60.7%

Oruka Therapeutics, Inc.ORKA

$6.81M+56.1%

Arbutus Biopharma CorporationABUS

$448K-59.0%

Alumis Inc.ALMS

$35.96M+3.6%

Polaryx Therapeutics, Inc.PLYX

$86K—

BioSig Technologies, Inc.STEX

$167K—

FAQ

What is Rigel Pharmaceuticals's accrued research and development?

Rigel Pharmaceuticals (RIGL) reported accrued research and development of $218K in Q1 2026.

How has Rigel Pharmaceuticals's accrued research and development changed year-over-year?

Rigel Pharmaceuticals's accrued research and development decreased by 62.1% year-over-year, from $575K to $218K.

What is the long-term trend for Rigel Pharmaceuticals's accrued research and development?

Over 2 years (2021 to 2023), Rigel Pharmaceuticals's accrued research and development has grown at a -12.6% compound annual growth rate (CAGR), from $5.5M to -$4.2M.

What does accrued research and development mean?

Represents the change in liabilities recognized for research and development activities that have been incurred but not yet paid. This metric tracks the timing differences between R&D work performed and the actual cash outflow to vendors or partners. It is a vital indicator of the company's R&D spending momentum and short-term liquidity management.